In androgen deprivation treatment of advanced prostate cancer, TRMT11 (tRNA methyltransferase 11) exhibited the strongest association with time to therapy failure (P < 0.001; FDR0.008; (40). Here, TRMT11 is linked to prostate carcinoma.